[{"id":"6b56b2f0-6f31-45d1-8ab6-6477c5f17c19","acronym":"RELATIVITY-1093","url":"https://clinicaltrials.gov/study/NCT06561386","created_at":"2025-02-25T14:04:42.242Z","updated_at":"2025-02-25T14:04:42.242Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","source_id_and_acronym":"NCT06561386 - RELATIVITY-1093","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/07/2024","start_date":" 10/07/2024","primary_txt":" Primary completion: 07/30/2030","primary_completion_date":" 07/30/2030","study_txt":" Completion: 11/11/2033","study_completion_date":" 11/11/2033","last_update_posted":"2025-02-19"},{"id":"c388e765-68a9-4c36-8000-4ede187305c8","acronym":"CA224-094","url":"https://clinicaltrials.gov/study/NCT04552223","created_at":"2021-01-18T21:45:58.107Z","updated_at":"2025-02-25T14:29:34.845Z","phase":"Phase 2","brief_title":"Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma","source_id_and_acronym":"NCT04552223 - CA224-094","lead_sponsor":"Jose Lutzky, MD","biomarkers":" LAG3 • CTLA4","pipe":"","alterations":" ","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/10/2020","start_date":" 11/10/2020","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2026","study_completion_date":" 01/04/2026","last_update_posted":"2025-02-13"},{"id":"cae2f24f-fcc5-4921-81fc-01d942260332","acronym":"RELATIVITY-060","url":"https://clinicaltrials.gov/study/NCT03662659","created_at":"2022-05-09T20:53:55.716Z","updated_at":"2025-02-25T16:44:27.386Z","phase":"Phase 2","brief_title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","source_id_and_acronym":"NCT03662659 - RELATIVITY-060","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" LAG3","pipe":"","alterations":" ","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Completed","enrollment":" Enrollment 274","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2025-02-05"},{"id":"f63dc019-68d2-4470-a8e6-c78d4c247511","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642067","created_at":"2021-01-18T17:52:44.817Z","updated_at":"2025-02-25T14:27:30.812Z","phase":"Phase 2","brief_title":"Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer","source_id_and_acronym":"NCT03642067","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/23/2024","primary_completion_date":" 02/23/2024","study_txt":" Completion: 09/18/2024","study_completion_date":" 09/18/2024","last_update_posted":"2025-01-28"},{"id":"72e4ff17-7877-4262-a51d-7d8c81b8c732","acronym":"Neo ReNi II","url":"https://clinicaltrials.gov/study/NCT05418972","created_at":"2022-06-15T16:54:46.563Z","updated_at":"2025-02-25T14:17:02.671Z","phase":"Phase 2","brief_title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","source_id_and_acronym":"NCT05418972 - Neo ReNi II","lead_sponsor":"Melanoma Institute Australia","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • NRAS wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2025-01-07"},{"id":"45c046f9-397a-49d4-a98d-7b69753ec117","acronym":"","url":"https://clinicaltrials.gov/study/NCT06295159","created_at":"2024-03-06T20:34:03.944Z","updated_at":"2025-02-25T14:18:50.824Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","source_id_and_acronym":"NCT06295159","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/17/2024","start_date":" 05/17/2024","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-12-17"},{"id":"949b2ac3-8269-489d-a405-99b472b2028a","acronym":"CA209-6D9","url":"https://clinicaltrials.gov/study/NCT05704933","created_at":"2023-01-30T15:59:33.242Z","updated_at":"2025-02-25T14:17:35.071Z","phase":"Phase 1","brief_title":"Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases","source_id_and_acronym":"NCT05704933 - CA209-6D9","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8 • PD-1 • IFNG • CD4 • IL2 • IL10","pipe":" | ","alterations":" PD-1 expression","tags":["CD8 • PD-1 • IFNG • CD4 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/06/2023","start_date":" 06/06/2023","primary_txt":" Primary completion: 06/07/2024","primary_completion_date":" 06/07/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-09"},{"id":"131edcdb-27c4-4090-85ed-cdfe17502f92","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743766","created_at":"2021-01-18T18:20:12.816Z","updated_at":"2025-02-25T14:27:49.581Z","phase":"Phase 2","brief_title":"Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting","source_id_and_acronym":"NCT03743766","lead_sponsor":"John Kirkwood","biomarkers":" PD-1 • LAG3","pipe":" | ","alterations":" PD-1 expression • LAG3 expression","tags":["PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":" Primary completion: 07/03/2024","primary_completion_date":" 07/03/2024","study_txt":" Completion: 07/03/2024","study_completion_date":" 07/03/2024","last_update_posted":"2024-09-25"},{"id":"4aeea117-34ac-4801-a9a7-3c04faeab1e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05912244","created_at":"2023-06-22T20:09:31.362Z","updated_at":"2025-02-25T16:18:54.885Z","phase":"Phase 2","brief_title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","source_id_and_acronym":"NCT05912244","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 06/09/2027","primary_completion_date":" 06/09/2027","study_txt":" Completion: 06/09/2027","study_completion_date":" 06/09/2027","last_update_posted":"2024-08-16"},{"id":"2aceb599-13fa-402f-b840-cf7cc183698c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05704647","created_at":"2023-01-30T15:59:29.626Z","updated_at":"2024-07-02T16:34:25.539Z","phase":"Phase 2","brief_title":"Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases","source_id_and_acronym":"NCT05704647","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/23/2023","start_date":" 02/23/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-17"},{"id":"2733b16c-4744-4169-8120-2555bfcf29cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867799","created_at":"2021-01-18T19:04:28.946Z","updated_at":"2024-07-02T16:34:26.092Z","phase":"Phase 2","brief_title":"iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer","source_id_and_acronym":"NCT03867799","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 10/21/2022","primary_completion_date":" 10/21/2022","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-06-14"},{"id":"189c84d8-9170-41ee-88a7-ba2d750c2705","acronym":"PRISM-MEL-301","url":"https://clinicaltrials.gov/study/NCT06112314","created_at":"2023-11-01T15:12:45.028Z","updated_at":"2024-07-02T16:34:26.248Z","phase":"Phase 3","brief_title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","source_id_and_acronym":"NCT06112314 - PRISM-MEL-301","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"73ce833b-3165-44c3-bd4f-85e8856dc262","acronym":"","url":"https://clinicaltrials.gov/study/NCT05629546","created_at":"2022-11-29T14:57:12.648Z","updated_at":"2024-07-02T16:34:27.538Z","phase":"Phase 1","brief_title":"Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors","source_id_and_acronym":"NCT05629546","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/30/2024","start_date":" 06/30/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2024-06-11"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"1c3bfa16-2be9-4d09-ac41-ccb0367eba8b","acronym":"Neo-MCC","url":"https://clinicaltrials.gov/study/NCT06151236","created_at":"2023-11-30T23:17:04.030Z","updated_at":"2025-02-25T14:18:31.410Z","phase":"Phase 2","brief_title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","source_id_and_acronym":"NCT06151236 - Neo-MCC","lead_sponsor":"Melanoma Institute Australia","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2024-03-15"},{"id":"5747d944-7a11-4d7b-99fe-396946a9c047","acronym":"RELATIVITY-123","url":"https://clinicaltrials.gov/study/NCT05328908","created_at":"2022-04-14T11:53:47.596Z","updated_at":"2024-07-02T16:35:16.804Z","phase":"Phase 3","brief_title":"A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05328908 - RELATIVITY-123","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • RAS wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Opdualag (nivolumab/relatlimab-rmbw)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 01/29/2025","primary_completion_date":" 01/29/2025","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2024-03-01"},{"id":"fd66e2fe-fd06-45f6-9687-e9f105e1a997","acronym":"","url":"https://clinicaltrials.gov/study/NCT04326257","created_at":"2021-01-18T20:57:23.420Z","updated_at":"2025-02-25T14:29:11.740Z","phase":"Phase 2","brief_title":"Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy","source_id_and_acronym":"NCT04326257","lead_sponsor":"Dan Zandberg","biomarkers":" LAG3 • CTLA4","pipe":" | ","alterations":" LAG3 expression • CTLA4 expression","tags":["LAG3 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression • CTLA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 08/12/2023","primary_completion_date":" 08/12/2023","study_txt":" Completion: 08/12/2024","study_completion_date":" 08/12/2024","last_update_posted":"2024-02-07"},{"id":"2873baef-f1cf-4885-998f-79e587c46fd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697576","created_at":"2021-01-19T20:49:52.733Z","updated_at":"2024-07-02T16:35:42.693Z","phase":"Phase 1","brief_title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","source_id_and_acronym":"NCT04697576","lead_sponsor":"Carlo Contreras","biomarkers":" CD20 • PD-1 • NCAM1 • GZMB • FOXP3","pipe":" | ","alterations":" TILs","tags":["CD20 • PD-1 • NCAM1 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-18"},{"id":"c4933379-acbb-484f-b02c-870362655c36","acronym":"","url":"https://clinicaltrials.gov/study/NCT05077280","created_at":"2021-10-14T20:56:30.510Z","updated_at":"2024-07-02T16:35:59.617Z","phase":"Phase 2","brief_title":"A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05077280","lead_sponsor":"California Pacific Medical Center Research Institute","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2022-12-06"}]